Sonus and HP finish contrast trial

Article

Developmental work continues on EchoGen, an ultrasound contrast agent from Sonus Pharmaceuticals. In conjunction with ultrasound scanner vendor Hewlett-Packard, Sonus has completed an image optimization trial that has determined the scanner control

Developmental work continues on EchoGen, an ultrasound contrast agent from Sonus Pharmaceuticals. In conjunction with ultrasound scanner vendor Hewlett-Packard, Sonus has completed an image optimization trial that has determined the scanner control parameters required to provide the highest level of cardiac image enhancement using its EchoGen ultrasound contrast agent.

The trial, which was conducted at the VA Medical Center in Dallas, consisted of 18 patients who were given EchoGen and then scanned using an HP Sonos 2500 LE echocardiography scanner. Sonos 2500 LE was designed for use in harmonic imaging studies with ultrasound contrast (SCAN 7/3/96).

In addition to determining optimal system settings, researchers found that on average, EchoGen demonstrated a persistence of at least five minutes, according to Sonus, which is headquartered in Bothell, WA.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.